H.R. 5461: Special Diabetes Program Reauthorization Act of 2025
Sponsor
Diana DeGette
Democrat · CO-1
Bill Progress
Latest Action · Sep 18, 2025
Referred to the House Committee on Energy and Commerce.
Congress wants to keep Type I diabetes research funded
Why it matters
$160 million a year is on the line. H.R. 5461 would keep a federal Type I diabetes funding stream running for five more years—$800 million total instead of letting the current authorization run out.
H.R. 5461 does one main thing: it extends funding for the Special Diabetes Programs for Type I diabetes. The bill sets that funding at $160 million for each fiscal year from 2026 through 2030.
Over five years, that adds up to $800 million in authorized funding. The bill also says the money stays available until spent, so it does not vanish just because the budget year ends.
What this bill does not do is just as important. It does not create a new diabetes benefit, change who qualifies for anything, add penalties, or launch a broader rewrite of federal diabetes policy. It is a continuation bill meant to prevent a funding gap.
H.R. 5461 Bill Summary
What H.R. 5461 actually does.
Type I diabetes funding continues for five years
H.R. 5461 authorizes $160 million a year for the Special Diabetes Programs for Type I diabetes for fiscal years 2026 through 2030.
Total authorized funding reaches $800 million
At $160 million a year for five years, the bill would authorize $800 million in total funding through 2030.
Money does not expire at year-end
The bill says the funds remain available until expended, giving agencies and grant recipients more flexibility to support multi-year work.
No new eligibility rules
The bill extends existing funding authority but does not add new age, income, or patient qualification standards.
No new reporting or penalties
H.R. 5461 does not create new fines, enforcement tools, or reporting deadlines. It is focused on funding continuity.
Who benefits from H.R. 5461?
People living with Type I diabetes
If your family is waiting on better treatments, prevention work, or long-term research progress, this bill is designed to keep that federal support from hitting a funding cliff.
Diabetes researchers and research institutions
A five-year authorization gives labs, universities, and partner institutions a clearer runway for projects that do not fit neatly inside a single budget year.
Organizations tied to the Special Diabetes Programs
Groups that rely on this federal program would get continuity: $160 million a year through 2030, with funds available until spent.
Families planning around Type I diabetes care and hope for new advances
This bill does not create immediate new benefits, but it aims to preserve the research and program support pipeline that families track closely.
Who is affected by H.R. 5461?
Federal health agencies running the program
They would continue administering the existing Type I diabetes funding stream for another five fiscal years under H.R. 5461.
Grant recipients and partner institutions
Their planning changes if Congress extends the program, because the bill provides a longer funding horizon instead of forcing year-to-year uncertainty.
Congress and budget writers
Lawmakers would be committing to an $800 million five-year authorization for this specific health program.
Anyone expecting a broader diabetes policy overhaul
This bill would not deliver that. It keeps an existing Type I diabetes program funded, but it does not expand benefits or rewrite federal diabetes rules.
Cost & Funding
Authorization
$160 million per fiscal year for 2026 through 2030, or $800 million total
- H.R. 5461 authorizes $160 million each year for five years.
- Back-of-the-napkin math: $160 million × 5 years = $800 million total authorized funding.
- The money is for the Special Diabetes Programs for Type I diabetes.
- Funds remain available until expended, so they can be used beyond the end of a single fiscal year.
- The bill extends an existing program rather than creating a new one.
HR5461 Legislative Journey
House: Committee Action
Sep 18, 2025
Referred to the House Committee on Energy and Commerce.
About the Sponsor
Diana DeGette
Democrat, Colorado's 1st congressional district · 29 years in Congress
Committees: Energy and Commerce
View full profile →
Cosponsors (49)
This bill has 49 cosponsors: 35 Democrats, 14 Republicans, reflecting bipartisan support. Cosponsors represent 25 states: Alabama, California, Delaware, and 22 more.
Gus Bilirakis
Republican · FL
Raul Ruiz
Democrat · CA
Bennie Thompson
Democrat · MS
Emanuel Cleaver
Democrat · MO
Jamie Raskin
Democrat · MD
Gwen Moore
Democrat · WI
Rashida Tlaib
Democrat · MI
David Joyce
Republican · OH
Lloyd Doggett
Democrat · TX
Nanette Barragán
Democrat · CA
Angie Craig
Democrat · MN
Maxine Waters
Democrat · CA
Committee Sponsors
Energy and Commerce Committee
8 of 54 committee members cosponsored
18 Democrats across this committee haven't cosponsored yet. Mobilize their constituents
H.R. 5461 Quick Facts
- Committee
- Energy and Commerce
- Chamber
- House
- Policy
- Health
- Introduced
- Sep 18, 2025
Referred to the House Committee on Energy and Commerce.
Sep 18, 2025
Official Sources
Official Congress.gov page for the Special Diabetes Program Reauthorization Act of 2025 with status, text, and actions.
The bill amends 42 U.S.C. 254c-2, the Public Health Service Act provision that authorizes the Special Diabetes Program for Type I diabetes.
GovInfo hosts the compiled Public Health Service Act, the underlying law amended by this bill.
CBO posts official cost estimates when available for legislation such as health program reauthorizations.
NIDDK is the NIH institute most closely associated with federal diabetes research supported through this program.
H.R. 5461 Common Questions
What does H.R. 5461 do?
It extends federal funding for the Special Diabetes Programs for Type I diabetes at $160 million a year from 2026 through 2030.
How much money is in H.R. 5461?
The bill authorizes $160 million per year for five years. That's $800 million total through 2030.
Does H.R. 5461 create new diabetes benefits for patients?
No. H.R. 5461 is a funding extension for an existing Type I diabetes program, not a new direct benefit program for patients.
Does the funding in H.R. 5461 expire each year?
No. The bill says the money remains available until expended, so it can be used after the fiscal year ends.
Who benefits if H.R. 5461 passes?
People with Type I diabetes could benefit indirectly, along with researchers, universities, and organizations that rely on this federal funding stream.
Does H.R. 5461 change who qualifies for diabetes programs?
No. The bill extends funding but does not add new age, income, or eligibility rules.
Does H.R. 5461 add new reports, penalties, or enforcement rules?
No. The bill text is limited to extending funding and does not add new fines, compliance rules, or reporting mandates.
Based on H.R. 5461 bill text
H.R. 5461 Bill Text
“To extend funding for Special Diabetes Programs for Type I diabetes.”
Source: U.S. Government Publishing Office
Get notified when H.R. 5461 moves
Committee votes, floor action, cosponsor changes — straight to your inbox.
Bill alerts + Legisletter's monthly briefing. Unsubscribe anytime.
Health Bills
9 related bills we're tracking
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Reported (Amended) by the Committee on Ways and Means. H. Rept. 119-333, Part I.
Oct 3, 2025
Mikaela Naylon Give Kids a Chance Act
Received in the Senate.
Dec 2, 2025
Improving Seniors’ Timely Access to Care Act of 2025
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 42 - 0.
Jul 15, 2026
CONNECT for Health Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 26, 2025
Momnibus Act
Referred to the Subcommittee on Health.
Apr 20, 2026
Right to Contraception Act
Referred to the House Committee on Energy and Commerce.
Feb 5, 2025
Women’s Health Protection Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 24, 2025
Medicare Patient Access and Practice Stabilization Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jan 31, 2025
EACH Act of 2025
Referred to the Subcommittee on Health.
Dec 19, 2025
Trending Right Now
Bills gaining momentum across Congress
Great American Outdoors Act 250
Ordered to be Reported in the Nature of a Substitute (Amended) by Voice Vote.
Jun 24, 2026
Humane Cosmetics Act of 2025
Referred to the House Committee on Energy and Commerce.
Feb 27, 2025
American Franchise Act
Ordered to be Reported (Amended) by the Yeas and Nays: 18 - 15.
Jul 21, 2026
Tracking Health in Congress? Monitor bills, track cosponsor momentum, and launch advocacy campaigns — all from one advocacy platform.